Navigation Links
Microparticle immune response modifier shows broad effects against recurrent or metastatic cancer
Date:4/21/2009

DENVER, CO and AUCKLAND, NZ (April 21, 2009) MIS416, a novel microparticle-based immune response modifier, demonstrated the ability to significantly reduce the number and size of metastatic tumors in preclinical mouse models of lung and breast cancers, Innate Therapeutics (formerly Virionyx Corporation) announced. Research presented today at the American Association of Cancer Research (AACR) meeting in Denver, CO by researchers from the Auckland, NZ company and their colleagues at the David Geffen School for Medicine, University of California, Los Angeles showed that MIS416 significantly inhibited tumor growth and the formation of metastases when tested as a stand-alone agent. When administered as an adjunct to localized tumor irradiation, MIS416 also demonstrated synergistic activity against the recurrence of lung tumors. Moreover, in a therapeutic cancer vaccine model, MIS administered as a single agent significantly induced an anti-tumor cellular immune response without the reintroduction of previously harvested tumor antigens. This successful induction of adaptive immunity correlated with inhibition of tumor growth.

"On the basis of these findings, MIS416 appears to be a good candidate for clinical evaluation as an adjunct to existing cancer therapies such as surgery and radiation," said Gill Webster, Ph.D., chief scientific officer of Innate Therapeutics, who led the poster presentation. "In this clinical setting, MIS416 therapy may be able to contribute significantly towards limiting tumor reoccurrence or metastatic disease."

Immune response modifiers (IMRs) are agents that target the body's immune system to combat disease by mobilizing and expanding a broad range of intrinsic host defence mechanisms. Unlike first generation IMRs such as Toll-like receptor agonists or interferon alpha, each of which have a limited spectrum of activity and lack the ability to treat a broad range of malignant diseases, MIS416 acts on multiple pathways simultaneously to activate a broad range of innate immune cell types that are central to the development of innate and adaptive anti-tumor responses.

Phase 1 Clinical Trials Planned

Innate Therapeutics noted that the company plans to shortly begin a Phase 1 clinical trial of MIS416 in New Zealand. "While this study will be the first formal clinical trial of MIS416 in humans, the drug has been used under compassionate release exemption to treat a small number of patients with chronic or life threatening illnesses including progressive multiple sclerosis and metastatic disease," said Simon Wilkinson, Innate Therapeutics' chief executive officer. "To date, MIS416 has shown itself to be safe and well tolerated in these patients. Extensive toxicity studies of the drug in animals have also shown excellent safety with those treated showing no adverse effects at doses up to 650 times in excess of doses likely to be used therapeutically in humans."

About MIS416

MIS416 is a novel 2nd generation, multi-modal IRM, comprising a microparticulate formation of naturally occurring, non-immunogenic, cytosolically active TLR-9 and NOD-2 agonists. Signaling pathways activated by these ligands act synergistically to activate a broad range of innate immune cell subsets that are central to the development of innate and adaptive immune responses.


'/>"/>

Contact: Joan Kureczka
JKureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
Source:Eurekalert

Related biology news :

1. Drug-embedded microparticles bolster heart function in animal studies
2. Device protects transplanted pancreatic cells from the immune system
3. Vitamin D may exacerbate autoimmune disease
4. New evidence explains poor infant immune response to certain vaccines, says MU researcher
5. Lombardi research: Monoclonal antibodies primed to become potent immune weapons against cancer
6. A paradigm shift in immune response regulation
7. New origin found for a critical immune response
8. HIV adapts to escape immune response
9. Frogs immune system is key in fight against killer virus
10. La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery
11. Molecule that suppresses immune response under study in type 1 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/21/2016)... , June 21, 2016 NuData Security announced ... new role of principal product architect and that ... director of customer development. Both will report directly ... officer. The moves reflect NuData,s strategic growth in ... to high customer demand and customer focus values. ...
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems is ... log work hours, for employers to make sure the right employees are actually signing ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
Breaking Biology Technology: